General Updates

29th June, 2026 The Corporate Relationship Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Dalal Street, Bandra East, Mumbai 400 001. Mumbai 400 051. Scrip Code: 539523 Scrip Symbol: ALKEM Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (“SEBI LODR Regulations”)- Updates on Acquisition. Dear Sir(s)/ Madam, This is in continuation of our earlier intimations dated 13th February, 2026 and 06th March, 2026, wherein the Stock Exchanges were informed that M/s. Alkem Medtech Private Limited, a wholly owned subsidiary of the Company in India (“Alkem Medtech”), intends to acquire at least 51% and up to 55% of the total issued equity share capital of M/s. Occlutech Holding AG(“Occlutech”), a company incorporated in Switzerland and had executed Share Purchase Agreement with inter alia the selling shareholders of Occlutech respectively. In this regard, we wish to inform you that on 26th June, 2026, Alkem Medtech has executed First Supplementary Agreement to Share Purchase Agreement dated 6th March, 2026 with inter alia the selling shareholders of Occlutech. A copy of this disclosure will be made available on the Company’s website in accordance with Regulation 30(8) of the SEBI LODR Regulations. Request you to kindly take the same on record. Sincerely, For Alkem Laboratories Limited Manish Narang President – Legal, Company Secretary & Compliance Officer Encl: a/a